Aarey Drugs & Pharmaceuticals reported a net profit of ₹396.76 lakh for the financial year ended March 31, 2026, compared to ₹402.39 lakh in the previous year. Revenue from operations for the year stood at ₹47,226.90 lakh, a slight decrease from ₹47,394.33 lakh in FY25. The board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026, at its meeting held on May 30, 2026. The company published an extract of the audited standalone financial results in "Active Times" and "Mumbai Lakshadweep" on June 2, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹155.74 lakh, a significant increase from ₹47.01 lakh in the same period last year. Revenue from operations for Q4FY26 surged to ₹18,947.24 lakh from ₹10,809.93 lakh in Q4FY25. The total income for the quarter was ₹18,904.29 lakh.

Financial Performance

The company's total expenses for FY26 were ₹47,295.19 lakh, marginally lower than ₹47,765.38 lakh in the previous year. Profit before tax for the year was ₹541.42 lakh, down from ₹610.19 lakh in FY25. The board also considered the statement of deviation or variation in the utilization of funds raised through convertible warrants.

Key Metrics

Auditor's Report

Statutory auditors Motilal & Associates LLP issued an audit report with an unmodified opinion on the financial results. The auditors emphasized that closing balances for debtors and creditors are subject to confirmation and relied upon management representation where confirmations were not available. The trading window, which was closed prior to the board meeting, will reopen 48 hours after the announcement of the results.

Aarey drugs & pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the mandatory certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Filing

The company submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to both BSE Limited and National Stock Exchange of India Limited on April 14, 2026. The certificate was signed by Director Nimit Ghatalia (DIN: 07069841) on behalf of the company.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Share Transfer Agent. The registrar issued the compliance certificate on April 3, 2026, confirming proper handling of securities dematerialisation processes during the quarter.

The certificate confirms that securities received from depository participants for dematerialisation were properly processed within prescribed timelines. MUFG Intime verified that security certificates received for dematerialisation were mutilated and cancelled after due verification, with depositories' names substituted in the register of members as registered owners.

Corporate Information

Aarey Drugs & Pharmaceuticals Limited operates as a manufacturer of bulk drugs and importer of solvents and chemicals. The company maintains its head office at Sahakar Bhavan, Mumbai, with its registered office and factory located at MIDC, Tarapur, Boisar in Thane district.

The submission of this quarterly compliance certificate reflects the company's adherence to SEBI regulations governing depositories and participants, ensuring transparency in securities handling and maintaining investor confidence through proper regulatory compliance.